Imagion Biosystems Limited has lodged Appendix 3X, Final Director’s Interest Notice, with the Australian Securities Exchange.
View the Final Director’s Interest Notice.
The Stock Network Interview – How MagSense® is moving towards Phase 2 clinical trials
September 4, 2026
Lel Smits from The Stock Network sat down with Imagion Biosystems’ Bob Proulx to discuss how the company is moving through the critical steps required